BioAge Labs Revenue

In the year 2025, BioAge Labs had annual revenue of $9.00M. BioAge Labs had revenue of $3.08M in the quarter ending December 31, 2025.

Revenue (ttm)

$9.00M

Revenue Growth

n/a

P/S Ratio

79.68

Revenue / Employee

$145,081

Employees

Market Cap

716.73M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	9.00M	-	-
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

BIOA News

2 months ago - BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewsWire
2 months ago - BioAge Announces Proposed Public Offering - GlobeNewsWire
2 months ago - BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - GlobeNewsWire
2 months ago - BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk - GlobeNewsWire
4 months ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
4 months ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
5 months ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
6 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire

More News